Sugi Predict

Sugi Predict / Compounds / Phenanthrene

Phenanthrene

Phenanthrene

SCHEMBL1673168

c1c[nH]cn1.c1ccc2c(c1)ccc1ccccc12

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.54
▸ FKBP5 Q13451 1/20 0.54
▸ HSD17B10 Q99714 2/20 0.50
▸ CYP2A6 P11509 2/20 0.50
▸ TSHR P16473 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ HPRT1 P00492 3/20 0.46
▸ CYP3A4 P08684 2/20 0.44
▸ HIF1A Q16665 1/20 0.43
▸ CYP1B1 Q16678 1/20 0.43
▸ MAPT P10636 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ APEX1 P27695 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ PMP22 Q01453 1/20 0.40
▸ PAX8 Q06710 1/20 0.39
▸ PARP1 P09874 1/20 0.36
▸ F12 P00748 1/20 0.36
▸ PLAU P00749 1/20 0.36
▸ NCF1 P14598 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Naphthalene SCHEMBL338629 0.87 ALDH1A1 (0.65) ALDH1A1FKBP5CYP2A6ADRA2A
Naphthalene SCHEMBL2123892 0.87 ALDH1A1 (0.65) ALDH1A1FKBP5CYP2A6ADRA2A
Phenanthrene SCHEMBL28829508 0.87 CYP3A4 (0.54) ALDH1A1FKBP5HSD17B10CYP2A6TSHR
Benzo[E]Pyrene SCHEMBL29274113 0.85 ALDH1A1 (0.57) ALDH1A1FKBP5HSD17B10CYP2A6TSHR
Naphthalene SCHEMBL27481708 0.85 ALDH1A1 (0.62) ALDH1A1FKBP5CYP2A6ADRA2A
Imidazole SCHEMBL27958457 0.83 CYP2A6 (0.59) ALDH1A1FKBP5CYP2A6CYP3A4MAPT
Imidazole SCHEMBL17145032 0.83 MAPT (0.47) ALDH1A1FKBP5HSD17B10CYP2A6CYP3A4
1-Naphthol SCHEMBL29142711 0.83 CYP1A2 (0.59) ALDH1A1FKBP5HSD17B10TSHRTDP1
Anthracene SCHEMBL28457231 0.83 ALDH1A1 (0.59) ALDH1A1FKBP5HSD17B10CYP2A6TDP1
Phenazine SCHEMBL28557583 0.83 ALDH1A1 (0.59) ALDH1A1FKBP5HSD17B10TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115572284-A Crosslinkable host material 三星显示有限公司 2023-01-06 — — CN claimed
US-20180334473-A1 Arene Ruthenium Complex, Preparation Method and Utilization Thereof GUANGDONG PHARMACEUTICAL UNIVERSITY (CN) 2018-11-22 — — US claimed
WO-2024112287-A1 BENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BANOGLU ERDEN (TR) 2024-05-30 — — WO disclosed
WO-2023284022-A1 PHENANTHROIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 广东工业大学 2023-01-19 — — WO disclosed
CN-115572284-A Crosslinkable host material 三星显示有限公司 2023-01-06 — — CN disclosed
CN-115477778-A Proton exchange membrane 中国科学院福建物质结构研究所 2022-12-16 — — CN disclosed
CN-108884390-B Intermediates and procedures for the synthesis of functional materials 默克专利股份有限公司 2022-05-31 — — CN disclosed
CN-114514627-A Organic electroluminescent green light emitting device 赛诺拉有限公司 2022-05-17 — — CN disclosed
CN-113659086-A White light organic electroluminescent device with low efficiency roll-off and high spectral stability and preparation method thereof 盐城吉研智能科技有限公司 2021-11-16 — — CN disclosed
CN-113659086-A White light organic electroluminescent device with low efficiency roll-off and high spectral stability and preparation method thereof 盐城吉研智能科技有限公司 2021-11-16 — — CN disclosed
CN-113214253-A Pyridoimidazole derivative and preparation method and application thereof 广东工业大学 2021-08-06 — — CN disclosed
EP-1954683-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO(9,10-D)IMIDAZOLES AS MPGES-1 INHIBITORS Merck Frosst Canada Ltd. (CA) 2008-08-13 — — EP disclosed
WO-2008084218-A1 BENZAZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-17 — — WO disclosed
WO-2007124589-A1 METHODS FOR TREATING OR PREVENTING NEOPLASIAS MERCK FROSST CANADA LTD. (CA) 2007-11-08 — — WO disclosed
US-20070208017-A1 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors MERCK CANADA INC. (CA) 2007-09-06 — — US disclosed
EP-1828143-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS Merck Frosst Canada Ltd. (CA) 2007-09-05 — — EP disclosed
WO-2007095753-A1 2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO [9,10-D] IMIDAZOLES MERCK FROSST CANADA LTD. (CA) 2007-08-30 — — WO disclosed
WO-2007059610-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2007-05-31 — — WO disclosed
WO-2007059611-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2007-05-31 — — WO disclosed
WO-2006063466-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208017-A1 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors PTGS1, PTGES, PTGES2 ALDH1A1 165/4885FKBP5 309/4885HSD17B10 1562/4885
US-20180334473-A1 Arene Ruthenium Complex, Preparation Method and Utilization Thereof CBR3, CBR1, C1R ALDH1A1 3559/4885FKBP5 1851/4885HSD17B10 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.